Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

Istituto Europeo di Oncologia, Milano, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:5City/State/Province:Milano
Treatments:Biologic therapyHospital:Istituto Europeo di Oncologia
Drugs:Journal:Link
Date:Oct 2013

Description:

Patients:
This phase 2 study involved 113 previously treated advanced triple-negative breast cancer patients. The median patient age was 52 years.

Treatment:
Patients were treated with the biologic therapy agent sunitinib, which is a receptor tyrosine kinase inhibitor that interferes with cancer cell growth.

Toxicities:
There were treatment-related deaths due to heart attack, disseminated vascular coagulation (increased blood clotting), and respiratory problems. Grade 4 diarrhea and abdominal pain were also reported.

Results:
The median overall survival was 9.4 months.

Support:
This study was supported by Pfizer Inc.

Correspondence: Dr. Giuseppe Curigliano; email: [email protected]



Back